


Amendments to the Claims


This listing of claims will replace all prior versions and listings of claims in the application.

1. (currently amended) A compound of general Formula I:



or a pharmaceutically acceptable salt thereof, wherein

R^1 , R^2 and R^3 in each instance is independently selected from the group consisting of hydrogen, halogen, C_{1-5} alkyl, cyano, carboxy(C_{1-5})alkyl, trifluoromethyl, nitro, methylamino, dimethylamino, halo(C_{1-5})alkyl, hydroxy(C_{1-5})alkyl, $(Bu)_3Sn$ -, $(Bu)_3Sn(C_{1-5})$ alkyl, formyl, and the tetradentate metal ligand moiety having the following formula:



wherein,

R^4 is selected from the group consisting of:

- a. C_{1-5} alkylthio,
- b. halo(C_{1-5})alkyl,

- c. halo(C₁₋₅)alkoxy,
- d. carboxy(C₁₋₅)alkyl,
- e. hydroxy,
- f. C₁₋₅ alkoxy,
- g. hydroxy(C₁₋₅)alkyl,
- h. NR⁵R⁶, wherein
R⁵ and R⁶ are independently hydrogen, halo(C₁₋₅)alkyl or
C₁₋₅ alkyl,
- i. phenyl(C₁₋₅)alkyl,
- j. C₆₋₁₀ aryl,
- k. heteroaryl,
- l. heterocycle,
- m. heterocycle(C₁₋₅)alkyl, and
- n. C₃₋₆ cycloalkyl,

wherein said phenyl(C₁₋₅)alkyl, C₆₋₁₀ aryl, heteroaryl,
heterocycle, heterocycle(C₁₋₅)alkyl or C₃₋₆ cycloalkyl is substituted
with one of the following: C₁₋₅ alkylthio, C₁₋₅ alkylsulfonyl,
methoxy, hydroxy, dimethylamino or methylamino,

R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁵, R²⁶, R²⁷, R²⁸ and R²⁹ are independently
selected from the group consisting of hydrogen, halogen, C₁₋₅ alkyl, cyano, carboxy(C₁₋₅)
alkyl, hydroxy(C₁₋₅)alkyl, trifluoromethyl, nitro, methylamino, dimethylamino,
halo(C₁₋₅)alkyl, phenyl(C₁₋₅)alkyl, C₃₋₆ cycloalkyl, heterocycle (C₁₋₅)alkyl and carbonyl,
and R^P is a ~~sulhydryl~~ sulhydryl protecting group,

and,

X is hydrogen, ¹²⁵I, ¹²³I, ¹³¹I, ¹⁸F, ⁷⁶Br, ⁷⁷Br or Sn(alkyl)₃.

2. (original) A compound of claim 1, wherein

R¹, R² and R³ are hydrogen or C₁₋₅ alkyl.

3. (original) A compound of claim 2, wherein

R¹, R² and R³ are hydrogen,

and,

R⁴ is halo(C₁₋₅)alkyl, hydroxy, C₁₋₅ alkoxy or NR⁵R⁶, wherein

R⁵ and R⁶ are independently hydrogen, halo(C₁₋₅)alkyl or C₁₋₅ alkyl.

4. (original) A compound of claim 3, wherein

R⁴ is NR⁵R⁶, wherein

R⁵ and R⁶ are independently hydrogen, halo(C₁₋₅)alkyl or C₁₋₅ alkyl.

5. (original) A compound of claim 1, wherein

X is ¹²³I or ¹⁸F.

6. (original) The compound of claim 1, wherein

R¹ is methylamino or dimethylamino,

R² is hydrogen,

R³ is halo(C₁₋₅)alkyl or (Bu₃)Sn(C₁₋₅)alkyl,

R⁴ is hydroxy or hydroxy(C₁₋₅)alkyl,

and,

X is hydrogen.

7. (original) The compound of claim 6, wherein

R¹ is dimethylamino,

R³ is ¹⁸fluoro(C₁₋₅)alkyl,


and,

R⁴ is hydroxy.

8. (original) The compound of claim 7, wherein R^3 is ^{18}F fluoromethyl or ^{18}F fluoroethyl.

9. (original) The compound of claim 8, wherein R^3 is ^{18}F fluoroethyl.

10. (currently amended) A compound of general Formula II:




or a pharmaceutically acceptable salt thereof, wherein:

R^9 and R^{10} in each instance is independently selected from the group consisting of:

- a. hydrogen,
- b. C_{1-5} alkyl,
- c. cyano,
- d. trifluoromethyl,
- e. nitro,
- f. halogen,
- g. hydroxy(C_{1-5})alkyl,
- h. halo(C_{1-5})alkyl,
- i. C_{1-5} alkylthio,
- j. halo(C_{1-5})alkoxy,
- k. carboxy(C_{1-5})alkyl,
- l. hydroxy,

- m. C₁₋₅ alkoxy,
 - n. NR¹¹R¹², wherein
R¹¹ and R¹² are independently hydrogen, halo(C₁₋₅)alkyl or C₁₋₅ alkyl,
 - o. phenyl(C₁₋₅)alkyl,
 - p. C₆₋₁₀ aryl,
 - q. heteroaryl,
 - r. heterocycle,
 - s. heterocycle(C₁₋₅)alkyl, and
 - t. C₃₋₆ cycloalkyl,
- wherein said phenyl(C₁₋₅)alkyl, C₆₋₁₀ aryl, heteroaryl, heterocycle, heterocycle(C₁₋₅)alkyl or C₃₋₆ cycloalkyl is substituted with one of the following: C₁₋₅ alkylthio, C₁₋₅ alkylsulfonyl, methoxy, hydroxy, dimethylamino or methylamino,
- u. the tetradentate metal ligand moiety having the following formula:



wherein, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁵, R²⁶, R²⁷, R²⁸ and R²⁹ are independently selected from the group consisting of hydrogen, halogen, C₁₋₅ alkyl, cyano, carboxy(C₁₋₅)alkyl, hydroxy(C₁₋₅)alkyl, trifluoromethyl, nitro, methylamino, dimethylamino, halo(C₁₋₅)alkyl, phenyl(C₁₋₅)alkyl, C₃₋₆ cycloalkyl,

heterocycle (C₁₋₅)alkyl and carbonyl, and R^P is a ~~sulhydryl~~
sulphydryl protecting group,

R⁷ and R⁸ in each instance is independently selected from the group consisting of hydrogen, hydroxy, C₁₋₅ alkyl, C₁₋₅ alkoxy, halogen, carboxy(C₁₋₅)alkyl, trifluoromethyl, and halo(C₁₋₅)alkyl, phenyl(C₁₋₅)alkyl, C₃₋₆ cycloalkyl, heterocycle(C₁₋₅)alkyl, or R⁷ and R⁸ can be taken together to form a carbonyl,

and,

X' is ¹²⁵I, ¹²³I, ¹³¹I, ¹⁸F, ⁷⁶Br, ⁷⁷Br or Sn(alkyl)₃.

11. (original) A compound of claim 10, wherein
R⁹ is hydrogen.

12. (original) A compound of claim 11, wherein
R⁷ and R⁸ in each instance is independently selected from the group consisting of hydrogen, hydroxyl, C₁₋₅ alkyl, halogen, and halo(C₁₋₅)alkyl, or R⁷ and R⁸ can be taken together to form a carbonyl.

13. (original) A compound of claim 12, wherein
R¹⁰ is selected from the group consisting of cyano, nitro and NR¹¹R¹², wherein
R¹¹ and R¹² are independently hydrogen or C₁₋₅ alkyl,

and,

R⁷ and R⁸ are independently hydrogen or hydroxyl.

14. (original) A compound of claim 13, wherein
R¹⁰ is NR¹¹R¹², wherein


R¹¹ and R¹² are independently hydrogen, methyl or ethyl,

and,

R^7 and R^8 are both hydrogen.

15. (original) The compound of claim 14, wherein X' is ^{123}I or ^{18}F .

16. (original) A compound of general Formula III:



or a pharmaceutically acceptable salt thereof, wherein:

n is zero or one,

R^{13} is selected from the group consisting of:

- a. C_{1-5} alkyl,
- b. cyano,
- c. trifluoromethyl,
- d. nitro,
- e. halo(C_{1-5})alkyl,
- f. C_{1-5} alkylthio,
- g. halogen,
- h. halo(C_{1-5})alkoxy,
- i. carboxy(C_{1-5})alkyl,
- j. hydroxy,
- k. hydroxy(C_{1-5})alkyl,
- l. C_{1-5} alkoxy,

- m. $\text{NR}^{14}\text{R}^{15}$, wherein
 R^{14} and R^{15} are independently hydrogen, halo(C_{1-5})alkyl or C_{1-5} alkyl,
- n. phenyl(C_{1-5})alkyl,
- o. C_{6-10} aryl,
- p. heteroaryl,
- q. heterocycle,
- r. heterocycle(C_{1-5})alkyl, and
- s. C_{3-6} cycloalkyl,

wherein said phenyl(C_{1-5})alkyl, C_{6-10} aryl, heteroaryl, heterocycle, heterocycle(C_{1-5})alkyl or C_{3-6} cycloalkyl is substituted with one of the following: C_{1-5} alkylthio, C_{1-5} alkylsulfonyl, methoxy, hydroxy, dimethylamino or methylamino,

R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} in each instance is independently selected from the group consisting of hydrogen, halogen, C_{1-5} alkyl, cyano, carboxy(C_{1-5})alkyl, hydroxy(C_{1-5})alkyl, trifluoromethyl, nitro, methylamino, dimethylamino, halo(C_{1-5})alkyl, phenyl(C_{1-5})alkyl, C_{3-6} cycloalkyl, heterocycle, heteroaryl, C_{6-10} aryl, (C_{1-5})alkyl and carbonyl,

and,

R^{P} is a sulfhydryl protecting group.

17. (original) A compound of claim 16, wherein
 R^{13} is $\text{NR}^{14}\text{R}^{15}$, wherein

R^{14} and R^{15} are independently hydrogen or C_{1-5} alkyl.

18. (original) A compound of claim 17, wherein
 n is one,

R^{16} and R^{17} are both hydrogen or are taken together to form a carbonyl,

and,

R^{18} , R^{19} , R^{22} , R^{23} , R^{24} and R^{25} in each instance is independently selected from the group consisting of hydrogen and C_{1-5} alkyl.

19. (original) A compound of claim 18, wherein R^{16} , R^{17} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} are hydrogen,

and,

R^{18} and R^{19} are both C_{1-5} alkyl.

20. (original) A compound of claim 18, wherein R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{24} and R^{25} are hydrogen,

and,

R^{22} and R^{23} are both C_{1-5} alkyl.

21. (original) A compound of claim 18, wherein R^{16} and R^{17} are taken together to form a carbonyl.

22. (original) A compound of claim 21, wherein R^{18} and R^{19} are both C_{1-5} alkyl,

and,

R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} are hydrogen.


23. (original) A compound of claim 21, wherein R^{18} , R^{19} , R^{20} , R^{21} , R^{24} and R^{25} are hydrogen,

and,

R^{22} and R^{23} are both C_{1-5} alkyl.

24. (original) A compound of claim 21, wherein R^{18} , R^{19} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} are hydrogen.

25. (currently amended) A radioisotope complex of a compound of claim 18 having the Formula:



provided that one of R^{24} and R^{25} is selected from the group consisting of:

- a. hydrogen,
- b. C_{1-5} alkyl,
- ~~b. trifluoromethyl,~~
- ~~c. halo(C_{1-5})alkyl,~~
- ~~d. carboxy(C_{1-5})alkyl,~~
- ~~e. phenyl(C_{1-5})alkyl,~~
- ~~f. C_{6-10} aryl,~~
- ~~g. heteroaryl,~~
- ~~h. heterocycle,~~
- ~~i. heterocycle(C_{1-5})alkyl, and~~
- ~~j. C_{3-6} cycloalkyl,~~
- c. trifluoromethyl,
- d. halo(C_{1-5})alkyl,

- e. carboxy(C₁₋₅)alkyl,
- f. phenyl(C₁₋₅)alkyl,
- g. C₆₋₁₀ aryl,
- h. heteroaryl,
- i. heterocycle,
- j. heterocycle(C₁₋₅)alkyl, and
- k. C₃₋₆ cycloalkyl,

wherein said phenyl(C₁₋₅)alkyl, C₆₋₁₀ aryl, heteroaryl, heterocycle, heterocycle(C₁₋₅)alkyl or C₃₋₆ cycloalkyl is substituted with one of the following: C₁₋₅ alkylthio, C₁₋₅ alkylsulfonyl, methoxy, hydroxy, dimethylamino or methylamino,

the other of R²⁴ and R²⁵ represents an unsubstituted position.

26. (original) A complex of claim 25, wherein

R¹³ is NR¹⁴R¹⁵, wherein

R¹⁴ and R¹⁵ are independently hydrogen or C₁₋₅ alkyl,

R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ are hydrogen,

R²⁴ and R²⁵ are hydrogen or unsubstituted,

and,

R²² and R²³ are both C₁₋₅ alkyl.

27. (original) The complex of claim 26, wherein


R¹⁴ and R¹⁵ are independently hydrogen or methyl,

R²⁴ and R²⁵ are unsubstituted,


and,

R²² and R²³ are both methyl.

28. (currently amended) The complex of claim 27 having the following structure:



29. (original) A compound of general Formula IV:




or a pharmaceutically acceptable salt thereof, wherein:

R^{13} , R^P , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} are as described for Formula III,


and,

R^7 and R^8 are as described for Formula II.

30. (currently amended) A radioisotope complex of a compound of claim 29 having the Formula:



31. (original) A compound of general Formula V:



V

or a pharmaceutically acceptable salt thereof, wherein:

R^{13} is selected from the group consisting of:

- a. C_{1-5} alkyl,
- b. cyano,
- c. trifluoromethyl,
- d. nitro,
- e. halo(C_{1-5})alkyl,
- f. C_{1-5} alkylthio,
- g. halogen,
- h. halo(C_{1-5})alkoxy,
- i. carboxy(C_{1-5})alkyl,
- j. hydroxy,
- k. hydroxy(C_{1-5})alkyl,
- l. C_{1-5} alkoxy,
- m. $NR^{14}R^{15}$, wherein
 R^{14} and R^{15} are independently hydrogen, halo(C_{1-5})alkyl or
 C_{1-5} alkyl,
- n. phenyl(C_{1-5})alkyl,
- o. C_{6-10} aryl,
- p. heteroaryl,
- q. heterocycle,
- r. heterocycle(C_{1-5})alkyl, and
- s. C_{3-6} cycloalkyl,


wherein said phenyl(C_{1-5})alkyl, C_{6-10} aryl, heteroaryl, heterocycle, heterocycle(C_{1-5})alkyl or C_{3-6} cycloalkyl is substituted with one of the following: C_{1-5} alkylthio, C_{1-5} alkylsulfonyl, methoxy, hydroxy, dimethylamino or methylamino,

and,

R^{30} and R^{31} are selected from the group consisting of hydrogen, hydroxy, hydroxy(C_{1-5})alkyl, C_{1-5} alkyl, C_{1-5} alkoxy, (C_{1-5})alkyl carboxy, halogen, carboxy(C_{1-5})alkyl, trifluoromethyl, and halo(C_{1-5})alkyl, phenyl(C_{1-5})alkyl, C_{3-6} cycloalkyl, heterocycle(C_{1-5})alkyl, provided,

if R^{13} is other than $NR^{14}R^{15}$, wherein one of R^{14} and R^{15} is $^{18}\text{Fluoro}(C_{1-5})\text{alkyl}$, then one of R^{30} and R^{31} is selected from the group consisting of ^{125}I , ^{123}I , ^{131}I , ^{18}F , ^{76}Br , ^{77}Br and $^{18}\text{Fluoro}(C_{1-5})\text{alkyl}$.

32. (original) A compound of general Formula VI:




or a pharmaceutically acceptable salt thereof, wherein:

R^{13} is as described for Formula V,

and,

R^P , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} , R^{22} , R^{23} , R^{24} and R^{25} are as described for Formula III.

33. (currently amended) A radioisotope complex of a compound of claim 32 having the Formula:



34. (currently amended) A pharmaceutical composition comprising a compound of any one of ~~claims 1-33~~ claims 1, 10 and 31.

35. (currently amended) A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of any one of ~~claims 1-33~~ claims 1, 10 and 31; and a pharmaceutically acceptable excipient or diluent.

36. A method of imaging amyloid deposits, comprising:
a. introducing into a mammal a detectable quantity of a diagnostic composition of claim 35; and

- b. allowing sufficient time for the labeled compound to be associated with amyloid deposits; and
- c. detecting the labeled compound associated with one or more amyloid deposits.